Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: "DEVALPO"

Change of nasal obstruction between Day 0 and Day 3

Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min between Day 0 (before use of the spray) and Day 3 (after use of the spray) (arm A). \[0 - 350 L/min\] 350 L/min means a better outcome.

Time frame: From Day 0 to Day 3

Immediate change of nasale obstruction at D0 on first use (Arm A)

Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min from pre- to post-spray measurements at Day 0 (arm A). \[ 0 - 350 L/min\] 350 L/min means a better outcome.

Time frame: At Day 0

Subjective feeling of reduced nasal obstruction on each day of use (arms A+B).

Proportion of patients with a reduction in the symptom "nasal obstruction" of at least 1pt, on SNOT22 (Sino-Nasal Outcome Test 22), and on each day of use (from Day 0 to Day 6) (arms A+B). This item is scaled from 0 to 5, 5 being the worst value.

Time frame: From Day 0 to Day 6

Subjective feeling of nasal cavity cleansing (freshness) each day of use (arms A+B).

Proportion of patients who experienced nasal cavity cleansing (feeling of freshness), on Patient Questionnaire, and on each day of use (from Day 0 to Day 6) (arms A+B).

Time frame: From Day 0 to Day 6

Subjective feeling of nasal secretion thinning on each day of use (arms A+B).

Proportion of patients with a change in the symptom "thick nasal discharge" of at least 1pt, on SNOT22, and on each day of use (Day 0 to Day 6) (arms A+B). This item is scaled from 0 to 5, 5 being the worst value.

Time frame: From Day 0 to Day 6

Subjective feeling of relief of nasal irritation (mucous membrane) on each day of use (arms A+B).

Proportion of patients who experienced relief of nasal (mucosal) irritation, on each day of use (Day 0 to Day 6) (arms A+B).

Time frame: From Day 0 to Day 6

Subjective feeling of relief of nasal itching on each day of use (arms A+B).

Proportion of patients who experienced relief of nasal itching, on Patient Questionnaire, and on each day of use (Day 0 to Day 6) (arms A+B).

Time frame: From Day 0 to Day 6

Speed of action at which the patient feels (subjectively) a decrease in nasal obstruction at D0 and D3 (arms A+B).

Proportion of patients with a change in immediate nasal obstruction after use of the spray, on Patient Questionnaire, at Day 0 and Day 3 (arms A+B).

Time frame: At Day 0 and Day 3

Speed of action at which the patient feels (subjectively) a purification of his nasal cavities (sensation of freshness) at D0 and D3 (arms A+B).

Proportion of patients who experienced immediate nasal cleansing (feeling of freshness) after use of the spray at Day 0 and Day 3 (arms A+B).

Time frame: At Day 0 and Day 3

Improvement in the patient's quality of life after 7 days of use (arms A+B).

Proportion of patients who experienced an improvement in quality of life, defined as an increase of at least 1pt on a scale of 0-10 between Day 0 and Day 6 (A+B arm). 10 mean a better value.

Time frame: From Day 0 to Day 6

Patient satisfaction with the medical device after 7 days of use (arm A+B).

Proportion of patients satisfied with the medical device, on a 4-point scale, at Day 6 (arm A+B). The better value is "very satisfied" and the worst value is "very unsatisfied". Proportion of patients who would recommend the medical device at Day 6 (arms A+B). Proportion of patients who will continue to use the medical device , and the reason if not, (arms A+B).

Time frame: At Day 6

Facility of use of the medical device after 7 days of use (arm A+B)

Proportion of patients who find the medical device easy to use, on day 6 (Arms A+B)

Time frame: At Day 6

Evolution of the overall severity of symptoms (arm A+B).

Mean SNOT22 score on each day. Comparison of SNOT22 score at Day 3 versus Day 0 baseline (arms A+B). \[ 0 to 220 \] 0 is the better value.

Time frame: At Day 0 and Day 3

Sensations of tingling and transient irritation (arms A+B).

Proportion of patients with at least 1 adverse event between 1st and last use of the medical device among the following adverse events (arms A+B): * Tingling sensations * Sensations of transient irritation

Time frame: From Day 0 to Day 6

All adverse events reported by patients using the pocket valve spray after 7 days of use (arm A+B).

All adverse events reported by the patient during the study (arm A+B).

Time frame: From Day 0 to Day 7